Autopsy report · NCT03445663

Study Evaluating AMG 424 in Subjects With Multiple Myeloma

“Previous sponsor business decision not to proceed with the AMG 424 asset.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 6 months before it started.
• Ran for about 1 year 11 months before it stopped.
• 27 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Xencor, Inc.

Sponsor type

Industry

Conditions

Relapsed/ Refractory Multiple Myeloma

Interventions

AMG 424

Participants

27

Sites

8

Countries

Australia, United States

Trials that died the same way

• Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal Cancer
  “Sponsor chose not to continue” (65% match in meaning)
• REGENETEN™ Bioinductive Implant System in Full-thickness Tears
  “Sponsor decision not related to safety.” (64% match in meaning)
• Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
  “Sponsor decision; the decision is not related to any safety concern.” (64% match in meaning)
• JSP191 Antibody Targeting Conditioning in SCID Patients
  “Sponsor Decision - terminated due to changes in company priorities and not related to safety concerns.” (64% match in meaning)
• The Surveillance Nonoperative Watch & Wait (SNOWW) Rectal Cancer Trial.
  “Sponsor decided not to move forward with the site.” (64% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.